Pre-surgery drugs for complex kidney cancer to save kidney
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving an immunotherapy drug (PD-L1 inhibitor) and an oral medication (anlotinib) before surgery can help shrink complex kidney tumors so that surgeons can remove only part of the kidney, preserving more kidney function. It may help you avoid losing your whole kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have clear cell renal cell carcinoma, the most common type of kidney cancer.
- Your tumor is at a stage where it can be removed by surgery (stage 2 or 3, not spread to distant organs).
- Your tumor is complex (based on a scoring system) and a kidney-sparing surgery (partial nephrectomy) is difficult but might be possible.
- You have not had any prior treatment for your kidney cancer (including surgery, chemotherapy, or immunotherapy).
- You do not have an active autoimmune disease, uncontrolled infections, or serious heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests whether giving two immunotherapy drugs before surgery can safely shrink kidney cancer tumors and help your body fight the cancer. You would receive the drugs before your scheduled surgery, and then your cancer would be removed as planned.
This trial tests if taking two drugs, belzutifan and pembrolizumab, before surgery can help shrink high-risk kidney cancer tumors and improve outcomes. It may be an option for people with locally advanced clear cell kidney cancer who are scheduled for nephrectomy.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.